Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
CLDX
CLDX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CLDX News
Celldex's Barzolvolimab Shows Strong Efficacy in Skin Conditions
Mar 02 2026
NASDAQ.COM
Celldex Presents Positive Data on Barzolvolimab for ColdU and SD Treatment
Mar 01 2026
Newsfilter
Celldex Reports Positive Data on Barzolvolimab Efficacy
Feb 27 2026
Newsfilter
Celldex Completes Enrollment for Barzolvolimab Trial Ahead of Schedule
Feb 26 2026
stocktwits
Celldex Q4 Earnings Miss Expectations
Feb 25 2026
seekingalpha
Celldex Completes Enrollment in Chronic Spontaneous Urticaria Studies Ahead of Schedule
Feb 25 2026
Yahoo Finance
Update: Celldex Therapeutics Completes Enrollment in Phase 3 Studies of Barzolvolimab; Shares Rise
Feb 25 2026
Yahoo Finance
Celldex Therapeutics Shares Surge 18% on Early Enrollment Completion
Feb 25 2026
seekingalpha
CLDX Stock Price Fluctuation Analysis
Feb 05 2026
NASDAQ.COM
Celldex Therapeutics' Jimenez Sells 4,166 Shares for $121,210
Jan 12 2026
Fool
Celldex Offers $25 Put Option, Attracting Investor Interest
Dec 22 2025
NASDAQ.COM
Celldex Initiates Global Phase 3 Trial for Cold Urticaria Treatment
Dec 09 2025
Globenewswire
Celldex Initiates Global Phase 3 Trial for Barzolvolimab Efficacy in ColdU and SD
Dec 09 2025
Newsfilter
Cleveland Diagnostics' IsoPSA Receives FDA Approval, Enhancing Prostate Biopsy Decision-Making
Dec 01 2025
Businesswire
Tech Stocks Surge, Palantir Soars 6% as Shutdown Resolution Approaches: Market Movers for Monday
Nov 10 2025
Benzinga
Celldex Appoints Teri Lawver as Chief Commercial Officer
Nov 10 2025
Newsfilter
Show More News
